Clinical Trials Browser

Active not recruiting × Breast Neoplasms × niraparib × Clear all

NCT04584255 2026-05-13

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms